Mechanisms of and obstacles to iron cardiomyopathy in thalassemia

Frontiers in Bioscience

Volumn 13, Issue 15, 2008, Pages 5975-5987

  Peng, Ching Tien ^a,b,c   Chang, Jeng Sheng ^a   Wu, Kang Hsi ^a,c   Tsai, Chang Hai ^a,b   Lin, Huan Sheng ^c  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b ASIA UNIVERSITY   (Taiwan)

^c Taiwan Thalassemia Association   (Taiwan)

Author keywords

Beta thalassemia; Cardioprotective chelation therapy; Iron cardiomyopathy; Iron cardiotoxicity; Mechanism; Review

Indexed keywords

DEFEROXAMINE; IRON; IRON CHELATING AGENT;

BLOOD PRESSURE; CARDIOMYOPATHY; CHEMICALLY INDUCED DISORDER; ELECTROCARDIOGRAPHY; HEART; HEART FAILURE; HUMAN; INTIMA; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; THALASSEMIA; TUNICA MEDIA;

BLOOD PRESSURE; CARDIOMYOPATHIES; DEFEROXAMINE; ELECTROCARDIOGRAPHY; HEART; HEART FAILURE; HUMANS; IRON; IRON CHELATING AGENTS; THALASSEMIA; TUNICA INTIMA; TUNICA MEDIA;

EID: 52049097257     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3130     Document Type: Review

References (112)

1. Weatherall, D.J. & J.B. Clegg: Inherited haemoglobin disorders: an increasing global health problem. Bull WHO 79, 704-712 (2001) (Pubitemid 32776838)
2. Olivieri, N.F.: The beta-thalassemias. N Engl J Med 341, 99-109 (1999)
3. Borgna-Pignatti, C., S. Rugolotto, P. De Stefano, H. Zhao, M.D. Cappellini, G.C. Del Vecchio, M.A. Romeo, G.I. Forni, M.R. Gamberini, R. Ghilardi, A. Piga & A. Cnaan: Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89, 1187-1193 (2004) (Pubitemid 39390442)
4. Aldouri, M.A., B. Wonke, A.V. Hoffbrand, D.M. Flynn, S.E. Ward, J.E. Agnew & A.J. Hilson: High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol 84, 113-117 (1990) (Pubitemid 20361934)
5. Vecchio, C. & G. Derchi: Management of cardiac complications in patients with thalassemia major. Semin Hematol 32, 288-296 (1995)
6. Huang, Y.C., J.S. Chang, K.H. Wu & C.T. Peng: Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in β-Thalassemia major patients. Hemoglobin 30, 229-238 (2006)
7. Vogel, M., L.J. Anderson, S. Hodden, J.E. Deanfield, D.J. Pennell & J.M. Walker: Tissue Doppler echocardiography in patients with thalassemia detects early myocardial dysfunction related to myocardial iron overload. Eur Heart J 24, 113-119 (2003) (Pubitemid 36109553)
8. Davis, B.A., C. O'Sullivan, P.H. Jarritt & J.B. Porter: Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 104, 263-269 (2004) (Pubitemid 38879867)
9. Gharzuddine, W.S., H.K. Kazma, I.A. Nuwayhid, F.F. Bitar, S.F. Koussa, G.V. Moukarbel & A.T. Taher: Doppler characterization of left ventricular diastolic function in beta-thalassaemia major. Evidence for an early stage of impaired relaxation. Eur J Echocardiogr 3, 47-51 (2002) (Pubitemid 34732726)
10. Kremastinos, D.T., D.P. Tsiapras, G.A. Tsetsos, E.I. Rentoukas, H.P. Vretou & P.K. Toutouzas: Left ventricular diastolic Doppler characteristics in beta-thalassemia major. Circulation 88, 1127-1135 (1993) (Pubitemid 23264030)
11. Davis, B.A. & J.B. Porter: Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 95, 1229-1236 (2000) (Pubitemid 30099831)
12. Peng, C.T., K.C. Chow, J.H. Chen, Y.P. Chiang, T.Y. Lin & C.H. Tsai: Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan. Eur J Haematol 70, 392-397 (2003)
13. Wu, K.H., J.S. Chang, C.H. Tsai & C.T. Peng: Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. Ann Hematol 83, 471-473 (2004) (Pubitemid 38877974)
14. Aessopos, A., D. Farmakis, A. Hatziliami, C. Fragodimitri, F. Karabatsos, J. Joussef, E. Mitilineou, E. Diamanti-Kandaraki, J. Meletis & M. Karagiorga: Cardiac status in well-treated patients with thalassemia major. Eur J Haematol 73, 359-366 (2004) (Pubitemid 39349917)
15. Jootar, P. & S. Fucharoen: Cardiac involvement in beta-thalassemia/hemoglobin E disease: clinical and hemodynamic findings. Southeast Asian J Trop Med Public Health 21, 269-273 (1990)
16. Vaccari, M., R. Crepaz, M. Fortini, M.R. Gamberini, S. Scarcia, W. Pitscheider & G. Bosi: Left ventricular remodeling, systolic function, and diastolic function in young adults with beta-thalassemia intermedia: a Doppler echocardiography study. Chest 121, 506-512 (2002) (Pubitemid 34132991)
17. Aessopos, A., D. Farmakis, M. Karagiorga, E. Voskaridou, A. Loutradi, A. Hatziliami, J. Joussef, J. Rombos & D. Loukopoulos: Cardiac involvement in thalassemia intermedia: a multicenter study. Blood 97, 3411-3416 (2001)
18. Forni, G.L. & G. Derchi: Typical manifestation of acute congestive heart failure in patients with thalassemia major causing diagnostic delay in the emergency room. Eur J Heart Fail 5, 607-608 (2003) (Pubitemid 38043964)
19. Wood, J.C., J.M. Tyszka, S. Carson, M.D. Nelson & T.D. Coates: Myocardial iron loading in transfusion-dependent thalassemia and sickle-cell disease. Blood 103, 1934-1936 (2004) (Pubitemid 38268994)
20. Borer, J.S., W.L. Henry & S.E. Epstein: Echocardiographic observations in patients with systemic infiltrative disease involving the heart. Am J Cardiol 39, 184-188 (1977) (Pubitemid 8043832)
21. Fitchett, D.H., D.J. Coltart, W.A. Littler, M.J. Levland, T. Trueman, D.I. Gozzard & T.J. Peters : Cardiac involvement in secondary haemochromatosis: a catheter biopsy study and analysis of myocardium. Cardiovasc Res 14, 719-724 (1980) (Pubitemid 11167199)
22. Barosi, G., E. Arbustini, A. Gavazzi, M. Grasso & A. Pucci: Myocardial iron grading by endomyocardial biopsy. A clinico-pathologic study on iron overloaded patients. Eur J Haematol 42, 382-388 (1989) (Pubitemid 19131449)
23. Glickstein, H., R.B. El, M. Shvartsman & Z.I. Cabantchik: Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood 106, 3242-3250 (2005) (Pubitemid 41565925)
24. Kyriacou, K., Y. Michaelides, R. Senkus, K. Simamonian, N. Pavlides, L. Antoniades & C. Zambartas: Ultrastructural pathology of the heart in patients with beta-thalassemia major. Ultrastruct Pathol 24, 75-81 (2000) (Pubitemid 30241158)
25. Sonakul, D., P. Pacharee, P. Wasi & S. Fucharoen: Cardiac pathology in 47 patients with beta thlassemia/hemoglobin E. Southeast Asian J Trop Med Public Health 15, 554-563 (1984) (Pubitemid 15077069)
26. Sonakul, D., K. Thakerngpol & P. Pacharee: Cardiac pathology in 76 thalassemic patients. Birth Defects Orig Artic Ser 23, 177-191 (1988)
27. Buja, L.M. & W.C. Roberts: Iron in the heart. Etiology and clinical significance. Am J Med 51, 209-221 (1971)
28. Schellhammer, P.F., M.A. Engle & W.C. Hagstrom: Histochemical studies of the myocardium and conduction system in acquired iron-storage disease. Circulation 35, 631-637 (1967)
29. Engle, M.A., M. Erlandson & C.H. Smith: Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation 30, 698-705 (1964)
30. Fucharoen, S. & P. Winichagoon: Hemoglobinopathies in Southeast Asia: molecular biology and clinical medicine. Hemoglobin 21, 299-319 (1997) (Pubitemid 27327182)
31. Sonakul, D., P. Pacharee, T. Laohapand, S. Fucharoen & P. Wasi: Pulmonary artery obstruction in thalassemia. Southeast Asian J Trop Med Public Health 11, 516-523 (1981)
32. Humbert, M., O. Sitbon, G. Simonneau: Treatment of pulmonary arterial hypertension. N Engl J Med 351, 1425-1436 (2004)
33. Hahalis, G., A.S. Manolis, D. Apostolopoulos, D. Alexopoulos, A.G. Vagenakis & N.C. Zoumbos: Right ventricular cardiomyopathy in beta-thalassemia major. Eur Heart J 23, 147-156 (2002) (Pubitemid 35204233)
34. Pepe, A., V. Positano, M.F. Santarelli, F. Sorrentino, E. Cracolici, D. De Marchi, A. Maggio, M. Midiri, L. Landini & M. Lombardi: Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. J Magn Reson Imaging 23, 662-668 (2006)
35. Advani, R., S. Sorenson, E. Shinar, W. Lande, E. Rachmilewitz & S.L. Schrier: Characterization and comparison of the RBC membrane damage in severe human alpha and beta thalassemia. Blood 79, 1058-1063 (1992)
36. Yuan, J., R. Kannan, E. Shinar, E.A. Rachmilewitz & P.S. Low: Isolation, characterization, and immunoprecipitation studies of immune complexes from membranes of beta-thalassemic erythrocytes. Blood 79, 3007-3013 (1992)
37. Gutteridge, J.M.C. & B. Halliwell: Iron toxicity and oxygen radicals. Baillieres Clin Haematol 2, 195-256 (1989) (Pubitemid 19128425)
38. Bacon, B.R., C.H. Park, G. Brittenham, R. O'Neill & A.S. Tavill: Hepatic mitochondrial oxidative metabolism in rats with chronic iron overload. Hepatology 5, 789-797 (1985) (Pubitemid 15236623)
39. Seymour, C.A. & T.J. Peters: Organelle pathology in primary and secondary haemochromatosis with special reference to lysosomal changes. Br J Haematol 40, 239-253 (1978) (Pubitemid 9040656)
40. Link, G., A. Athias, A. Grynberg, A. Pinson & C. Hershko: Effect of iron loading on transmembrane potential, contraction, and automaticity of rat ventricular muscle cells in culture. J Lab Clin Med 113, 103-111 (1989) (Pubitemid 19035190)
41. Hahalis, G., A. Kalogeropoulos, A. Chrysanthopoulou, E. Arvanitopoulou, A. Kourakli, A. Thomaidi, G. Terzis, C. Stathopoulos, D. Alexopoulos & A.S. Manolis: Endothelial function is impaired and intina-media thickness of the common carotid arterial wall is increased in patients with beta-thalassemia major (abstract). J Am Coll Cardiol 39, 220A (2002)
42. Livrea, M.A., L. Tesoriere, A.M. Pintaudi, A. Calabrese, A. Maggio, H.J. Freisleben, D. D'Arpa, R. D'Anna & A. Bongiorno: Oxidative stress and antioxidant status in beta-thalassemia major: iron overload and depletion of lipid-soluble antioxidants. Blood 88, 3608-3614 (1996) (Pubitemid 26365599)
43. Nitenberg, A., F. Paycha, S. Ledoux, R. Sachs, J.R. Attali & P. Valensi: Coronary artery responses to physiological stimuli are improved by deferoxamine but not by L-arginine in non-insulin-dependent diabetic patients with angiographically normal coronary arteries and no other risk factors. Circulation 97, 736-743 (1998) (Pubitemid 28135335)
44. Wolfe, L., N. Olivieri, D. Sallan, S. Colan, V. Rose, R. Propper, M.H. Freedman & D.G. Nathan: Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 312, 1600-1603 (1985) (Pubitemid 15062652)
45. Anderson, L.J., M.A. Westwood, S. Holden, B. Davis, E. Prescott, B. Wonke, J.B. Porter, J.M. Walker & D.J. Pennell: Myocardial iron clearance with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 127, 348-355 (2004) (Pubitemid 39468951)
46. Parkes, J.G., N.F. Olivieri & D.M. Templetion: Characterization of Fe2+ and Fe3+ transport by iron-loaded cardiac myocytes. Toxicology 117, 141-151 (1997) (Pubitemid 27087488)
47. Liu, Y., J.G. Parkes & D.M. Templetion: Differential accumulation of non-transferrin-bound iron by cardiac myocytes and fibroblasts. J Mol Cell Cardiol 35, 505-514 (2003) (Pubitemid 36539456)
48. Parkes, J.G., R.A. Hussain, N.F. Olivieri & D.M. Templetion: Effects of iron loading on uptake, speciation, and chelation of iron in cultured myocardial cells. J Lab Clin Med 122, 36-47 (1993) (Pubitemid 23206872)
49. Oudit, G.Y., H. Sun, M.G. Trivieri, S.E. Koch, F. Dawood, C. Ackerley, M. Yazdanpanah, G.J. Wilson, A. Schwartz, P.P. Liu & P.H. Backx: L-Type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med 9, 1187-1194 (2003) (Pubitemid 37173704)
50. Randell, E.W., J.G. Parkes, N.F. Olivieri & D.M. Templetion: Uptake of non-transferrin-bound iron by both reductive and nonreductive processes is modulated by intracellular iron. J Biol Chem 269, 16046-16053 (1994) (Pubitemid 24209290)
51. Esposito, B.P., W. Breuer, P. Sirankapracha, P. Pootrakul, C. Hershko & Z.I. Cabantchik: Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 102, 2670-2677 (2003) (Pubitemid 37193611)
52. Shiloh, H., T.C. Iancu, E.R. Bauminger, G. Link, A. Pinson & C. Hershko: Deferoxamine-induced iron mobilization and redistribution of myocardial iron in cultured rat heart cells: studies of the chelatable iron pool by electron microscopy and Mossbauer spectroscopy. J Lab Clin Med 119, 428-436 (1992)
53. Stuhne-Sekalec, L., S.X. Xu, J.G. Parkes, N.F. Olivieri & D.M. Templeton: Speciation of tissue and cellular iron with on-line detection by inductively coupled plasma-mass spectrometry. Anal Biochem 205, 278-284 (1992)
54. Iancu, T.C., H. Shiloh, G. Link, E.R. Bauminger, A. Pinson & C. Hershko: Ultrastructural pathology of iron-loaded rat myocardial cells in culture. Br J Exp Pathol 68, 53-65 (1987) (Pubitemid 17029356)
55. Wood, J.C., J. Fassler & T. Meade: Mimicking liver iron overload using liposomal ferritin preparations. Magn Reson Med 51, 607-611 (2004) (Pubitemid 38298676)
56. Kuryshev, Y.A., G.M. Brittenham, H. Fujioka, P. Kannan, C.C. Shieh, S.A. Cohen & A.M. Brown: Decreased sodium and increased transient outward potassium currents in iron-loaded cardiac myocytes. Implications for the arrhythmogenesis of human siderotic heart disease. Circulation 100, 675-683 (1999) (Pubitemid 29379759)
57. Selden, C., M. Owen, J.M. Hopkins & T.J. Peters: Studies on the concentration and intracellular localization of iron proteins in liver biopsy specimens from patients with iron overload with special reference to their role in lysosomal disruption. Br J Haematol 44, 593-603 (1980) (Pubitemid 10129170)
58. Link, G., A. Pinson & C. Hershko: Iron loading of cultured cardiac myocytes modifies sarcolemmal structure and increases lysosomal fragility. J Lab Clin Med 121, 127-134 (1993) (Pubitemid 23081768)
59. Link, G., A. Saada, A. Pinson, A.M. Konijn & C. Hershko: Mitochondrial respiratory enzymes are a major target of iron toxicity in rat heart cells. J Lab Clin Med 131, 466-474 (1998) (Pubitemid 28259763)
60. Rrussell, L.K., B.N. Finck & D.P. Kelly: Mouse models of mitochondrial dysfunction and heart failure. J Mol Cell Cardiol 38, 81-91 (2005) (Pubitemid 40038654)
61. Parkes, J.G., Y. Liu, J.B. Sirna & D.M. Templetion: Changes in gene expression with iron loading and chelation in cardiac myocytes and non-myocytic fibroblasts. J Mol Cell Cardiol 32, 233-246 (2000) (Pubitemid 30670346)
62. Liu, Y. & D.M. Templetion: The effects of cardiac myocytes on interstitial fibroblasts in toxic iron overload. Cardiovasc Toxicol 1, 299-308 (2001)
63. Laurita, K.R., E.T. Chuck, T. Yang, W.Q. Dong, Y.A. Kuryshev, G.M. Brittenham, D.S. Rosenbaum & A.M. Brown: Optical mapping reveals conduction slowing and impulse block in iron-overload cardiomyopathy. J Lab Clin Med 142, 83-89 (2003) (Pubitemid 37130040)
64. Kim, E., S.N. Giri & I.N. Pessah: Iron(II) is a modulator of ryanodine-sensitive calcium channels of cardiac muscle sarcoplasmic reticulum. Toxicol Appl Pharmacol 130, 57-66 (1995)
65. Pogwizd, S.M. & D.M. Bers: Cellular basis of triggered arrhythmias in heart failure. Trends Cardiovasc Med 14, 61-66 (2004) (Pubitemid 38340848)
66. Anderson, L.J., S. Holden, B. Davis, E. Prescott, C.C. Charrier, N.H. Bunce, D.N. Firmin, B. Wonke, J. Porter, J.M. Walker & D.J. Pennell: Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 22, 2171-2179 (2001) (Pubitemid 33139463)
67. Hahalis, G., A.S. Manolis, I. Gerasimidou, D. Alexopoulos, G. Sitafidis, A. Kourakli, R. Korfer, M.M. Koerner, A.G. Vagenakis & N.C. Zoumbos: Right ventricular diastolic function in beta-thalassemia major: echocardiographic and clinical correlates. Am Heart J 141, 428-434 (2001) (Pubitemid 32200272)
68. Johnston, D.L., L. Rice, G.W. Vick, T.D. Hedrick & R. Rokey: Assessment of tissue iron overload by nuclear magnetic resonance imaging. Am J Med 87, 40-47 (1989) (Pubitemid 19179408)
69. Brittenham, G.M., P.M. Griffith, A.W. Nienhuis, C.E. McLaren, N.S. Young, E.E. Tucker, C.J. Allen, D.E. Farrell & J.W. Harris: Efficacy of deferioxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 331, 567-573 (1994) (Pubitemid 24265698)
70. Voskaridou, E., M. Douskou, E. Terpos, I. Papassotiriou, A. Stamoulakatou, A. Ourailidis, A. Loutradi & D. Loukopoulos: Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassemia and sickle cell disease. Br J Haematol 126, 736-742 (2004) (Pubitemid 39221312)
71. Sylvie, V., L.D. Sebastien, K.E. Thomas, P. Dominique, G. Sabrina, B. Abdellah, V.K. Srini, S.R. Jean-Marie & G. Claude: Predictors of abnormal myocardial function and T2* in children and young adults with thalassemia major. Blood 102, 952a (2003)
72. Westwood, M.A., L.J. Anderson, M.A. Tanner & D.J. Pennell: The relationship between myocardial iron deposition and left ventricular dysfunction in thalassemia using cardiovascular magnetic resonance. J Cardiovasc Magn Reson 7, 46-47 (2005)
73. Olivieri, N.F. & G.M. Brittenham: Iron-chelating therapy and the treatment of thalassemia. Blood 89, 739-761 (1997) (Pubitemid 27121266)
74. Kremastinos, D.T., G.A. Tsetsos, D.P. Tsiapras, G.K. Karavolias, V.A. Ladis & C.A. Kattamis: Heart failure in beta-thalassemia: a 5-year follow-up study. Am J Med 111, 349-354 (2001) (Pubitemid 32913666)
75. Modell, B., M. Khan & M. Darlison: Survival in beta thalassaemia major in the UK: data from the UK thalassaemia register. Lancet 355, 2051-2052 (2000) (Pubitemid 30339248)
76. Lorey, F.: Asian immigration and public health in California: thalassemia in newborns in California. Pediatr Hematol Oncol 22, 564-566 (2000)
77. Wood, J.C., M. Otto-Duessel, M. Aguilar, H. Nick, M.D. Nelson, T.D. Coates, H. Pollack & R. Moats: Cardiac MRI (T2, T2*) predicts cardiac iron in the gerbil model of iron cardiomyopathy. Circulation 112, 535-543 (2005) (Pubitemid 41060794)
78. Wang, Z.J., L. Lian, Q. Chen, H. Zhao, T. Asakura & A.R. Cohen: 1/T2 and magnetic susceptibility measurements in a gerbil cardiac iron overload model. Radiology 234, 749-755 (2005) (Pubitemid 40250818)
79. Cheung, Y.F., G.C. Chan & S.Y. Ha: Arterial stiffness and endothelial function in patients with beta-thalassemia major. Circulation 106, 2561-2566 (2002) (Pubitemid 35340692)
80. Felker, G.M., R.E. Thompson, J.M. Hare, R.H. Hruban, D.E. Clemetson, D.L. Howard, K.L. Baughman & E.K. Kasper: Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342, 1077-1084 (2000) (Pubitemid 30207690)
81. Engle, M.A.: Cardiac involvement in Cooley's anemia. Ann N Y Acad Sci 119, 694-702 (1969)
82. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 325, 293-302 (1991)
83. Miskin, H., I. Yaniv, M. Berant, C. Hershko & H. Tamary: Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation. Eur J Haematol 70, 398-403 (2003) (Pubitemid 36713936)
84. Borgna-Pignatti, C., S. Rugolotto, P. De Stefano, A. Piga, F. Di Gregorio, M.R. Gamberini, V. Sabato, C. Melevendi, M.D. Cappellini & G. Verlato: Survival and disease complications in thalassemia major. Ann N Y Acad Sci 850, 227-231 (1998) (Pubitemid 28369763)
85. Olivieri, N.F., D.G. Nathan, J.H. MacMillan, A.S. Wayne, P.P. Liu, A. McGee, M. Martin, G. Koren & A.R. Cohen: Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 331, 574-578 (1994) (Pubitemid 24265699)
86. Zurlo, M.G., P. De Stefano, C. borgna-Pignatti, A. Di Palma, A. Piga, C. Melevendi, F. Di Gregorio, M.G. Burattini & S. Terzoli: Survival and causes of death in thalassemia major. Lancet 2, 27-30 (1989) (Pubitemid 19158169)
87. Sermsappasuk, P., M. Baek & M. Weiss: Kinetic analysis of myocardial uptake and negative inotropic effect of amiodarone in rat heart. Eur J Pharm Sci 28, 243-248 Epub (2006) (Pubitemid 43766099)
88. Hunt, S.A., D.W. Baker, M.H. Chin, M.P. Cinquegrani, A.M. Feldman, G.S. Francis, T.G. Ganiats, S. Goldstein, G. Gregoratos, M.L. Jessup, R.J. Noble, M. Packer, M.A. Silver, L.W. Stevensom, R.J. Gibbons, E.M. Antman, J.S. Alpert, D.P. Faxon, V. Fuster, A.K. Jacobs, L.F. Hiratzka, R.O. Russell & S.C. Jr Smith: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 38, 2101-2113 (2001) (Pubitemid 33116591)
89. Galanello, R., A. Kattamis, A. Piga, R. Fischer, G. Leoni, V. Ladis, V. Voi, U. Lund & F. Tricta: A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica 91, 1159-1161 (2006)
90. Kattamis, A., V. Ladis, H. Berdousi, N.L. Kelekis, E. Alexopoulou, I. Papasotiriou, K. Drakaki, I. Kaloumenou, A. Galani & C. Kattamis: Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. Blood Cells Mol Dis 36, 21-25 (2006) (Pubitemid 43061483)
91. Karvounis, H.I., T.A. Zaglavara, G.E. Parharidis, I.G. Nouskas, E.P. Hassapopoulou, K.D. Gemitzis & G.E. Louridas: An angiotensin-converting enzyme inhibitor improves left ventricular systolic and diastolic function in transfusion-dependent patients with beta-thalassemia major. Am Heart J 141, 281 (2001)
92. Littera, R., G. La Nasa, G. Derchi, M.D. Cappellini, C.Y. Chang & L. Contu: Long-term treatment with sildenafil in a thalassemic patient with pulmonary hypertension. Blood 100, 1516-1517 (2002) (Pubitemid 34864323)
93. Derchi, G., G.L. Forni, F. Formisano, M.D. Cappellini, R. Galanello, G. D'Ascola, P. Bina, C. Magnano & M. Lamagna: Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica 90, 452-458 (2005) (Pubitemid 40592887)
94. Gladwin, M., V. Sachdev, M.L. Jison, Y. Shizukuda, J.F. Plehn, K. Minter, B. Brown, W. Coles, J. Nichols, I. Ernst, L. Hunter, W. Blackwelder, A. Schechter, G. Rodgers, O. Castro & F. Ognibene: Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 350, 886-895 (2004) (Pubitemid 38252536)
95. Koerner, M.M., G. Tenderich, K. Minami, E. Zu Knyphausen, H. Mannebach, K. Kleesiek, H. Meyer & R. Koerfer: Heart transplantation for end-stage heart failure caused by iron overload. Br J Haematol 97, 293-296 (1997) (Pubitemid 27224606)
96. Tsironi, M., S. Deftereos, P. Andriopoulos, D. Farmakis, J. Meletis & A. Aessopos: Reversal of heart failure in thalassemia major by combined chelation therapy: a case report. Eur J Haematol 74, 84-85 (2005) (Pubitemid 40143694)
97. Abraham, W.T. & D.L. Hayes: Cardiac resynchronization therapy for heart failure. Circulation 108, 2596-2603 (2003) (Pubitemid 37466796)
98. Link, G., R. Tirosh, A. Pinson & C. Hershko: Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart mitochondria as a major site of iron-anthracycline interaction. J Lab Clin Med 127, 272-278 (1996) (Pubitemid 126657307)
99. Eldor, A. & E.A. Rachmilewitz: The hypercoagulable state in thalassemia. Blood 99, 36-43 (2002)
100. Worwood, M., S.J. Cragg, A. Jacobs, C. McLaren, C. Ricketts & J. Economidou: Binding of serum ferritin to concanavalin A: patients with homozygous beta-thalassemia and transfusional iron overload. Br J Haematol 46, 409-416 (1980) (Pubitemid 11226404)
101. Gabutti, V. & A. Piga: Results of long-term iron-chelating therapy. Acta Haematol 95, 26-36 (1996) (Pubitemid 26071428)
102. Basel, Switzerland: Desferal R Product Monograph. Novartis Inc (1998)
103. Anderson, L.J., B. Wonke, E. Prescott, S. Holden, J.M. Walker & D.J. Pennell: Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassemia. Lancet 360, 516-520 (2002) (Pubitemid 35232104)
104. Pennell, D.J., V. Berdoukas, M. Karagiorga, V. Ladis, A. Piga, A. Aessopos, E.D. Gotsis, M.A. Tanner, G.C. Smith, M.A. Westwood, B. Wonke & R. Galanello: Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 107, 3738-3744 (2006)
105. Piga, A., C. Gagliotic, E. Fogliacco & F. Tricta: Comparative effects of deferioprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 88, 489-496 (2003) (Pubitemid 36648438)
106. Borgna-Pignatti, C., M.D. Cappellini, P. De Stefano, G.C. Del Vecchio, G.L. Forni, M.R. Gamberini, R. Ghilardi, A. Piga, M.A. Romeo, H. Zhao & A. Cnaan: Cardiac morbility and mortality in deferoxamine-or deferiprone-treated patients with thalassemia major. Blood 107, 3733-3737 (2006)
107. Olivieri, N.F., S. De Silva, A. Premawardena, S. Sharma, A. Viens, C.M. Taylor, G.M. Brittenham & D.J. Weatherall: Iron overload and iron-chelating therapy in hemoglobin E-beta thalassemia. J Pediatr Hematol Oncol 22, 593-597 (2000)
108. Pootrakul, P., P. Sirankapracha, J. Sankote, U. Kachintorn, W. Maungsub, K. Sriphen, K. Thakernpol, K. Atisuk, S. Fucharoen, U. Chantraluksri, O. Shalev & A.V. Hoffbrand: Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol 122, 305-310 (2003) (Pubitemid 36859618)
109. Mourad, H.F., V.A. Hoffbrand, M. Sheikh-Taha, S. Koussa, I.A. Khoriaty & A. Taher: Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overload thalassaemia patients. Br J Haematol 121, 187-189 (2003) (Pubitemid 36461288)
110. Kontoghiorges, J.G., K. Pattichi, M. Hadjigavriel & A. Kolnagou: Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). Transfus Sci 23, 211-223 (2000)
111. Piga, A., R. Galanello, G.L. Forni, M.D. Cappellini, R. Origa, A. Zappu, G. Donato, E. Bordone, A. Lavagetto, L. Zanaboni, R. Sechaud, N. Hewson, J.M. Ford, H. Opitz & D. Alberti: Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 91, 873-880 (2006) (Pubitemid 44023139)
112. Nienhuis, A.W., H. Hanawa, N. Sawai & B.P. Sorrentino, D.A. Persons: Development of gene therapy for hemoglobin disorders. Ann N Y Acad Sci 996, 101-111 (2003) (Pubitemid 36706592)